Terns Pharma Q2 EPS $(0.31) Beats $(0.34) Estimate
Portfolio Pulse from Benzinga Newsdesk
Terns Pharma (NASDAQ:TERN) reported a Q2 EPS loss of $(0.31), beating the analyst consensus estimate of $(0.34) by 8.82%. This represents a 24% increase in losses compared to $(0.25) per share from the same period last year.
August 05, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Terns Pharma reported a Q2 EPS loss of $(0.31), which is better than the analyst estimate of $(0.34). However, the losses have increased by 24% compared to the same period last year.
The better-than-expected EPS loss is a positive short-term indicator for Terns Pharma, suggesting that the company is performing better than analysts anticipated. However, the year-over-year increase in losses may temper some of the optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100